 Hey, I want to invite you to join Stocktwits. It’s the largest global community of active traders. You’ll get access to the real-time market insights, news, discussion and much more! You can sign up using my unique link below 
 


 has invited you to join Stocktwits

Six abstracts selected for presentation, including three oral presentationsWALTHAM, Mass., Oct. 12, 2022 (GLOBE NEWSWIRE) -- Entasis Therapeutics Holdings Inc., a late-stage clinical biopharmaceutical company focused on the discovery and development of novel antibacterial products, and wholly owned ...

Entasis Therapeutics, a Wholly Owned Subsidiary of Innoviva, Announces Data on SUL-DUR to be Presented at IDWeek 2022

Entasis Therapeutics Holdings Inc. (NASDAQ:ETTX  Get Rating) major shareholder Innoviva, Inc. acquired 7,598,814 shares of Entasis Therapeutics stock in a transaction that occurred on Monday, July 11th. The stock was acquired at an average cost of $2.20 per share, with a total value of $16,...

Innoviva, Inc. Purchases 7,598,814 Shares of Entasis Therapeutics Holdings Inc. (NASDAQ:ETTX) Stock

Entasis Therapeutics Holdings Inc. (NASDAQ:ETTX  Get Rating) major shareholder Innoviva, Inc. bought 7,598,814 shares of the companys stock in a transaction on Monday, July 11th. The stock was purchased at an average cost of $2.20 per share, with a total value of $16,717,390.80. ...

Entasis Therapeutics Holdings Inc. (NASDAQ:ETTX) Major Shareholder Innoviva, Inc. Acquires 7,598,814 Shares

Innoviva, Inc. (Nasdaq: INVA) (Innoviva) today announced that its tender offer to purchase any and all issued and outstanding shares of common stock of Entasis Therapeutics Holdings Inc. (Nasdaq: ETTX) (Entasis) at a price of $2.20 per share, net to the seller in cash, without interest and less...

Innoviva Announces Expiration of Cash Tender Offer for Shares of Entasis Therapeutics Holdings Inc.

SHAREHOLDER NOTICE: Halper Sadeh LLP Investigates TMX, HR, MN, MICT, ETTX SHAREHOLDER NOTICE: Halper Sadeh LLP Investigates TMX, HR, MN, MICT, ETTX PR Newswire NEW YORK, June 22, 2022 NEW YORK, June 22, 2022 /PRNewswire/ --Halper Sadeh LLP, an investor rights law firm, is investigating the...

SHAREHOLDER NOTICE: Halper Sadeh LLP Investigates TMX, HR, MN, MICT, ETTX

SHAREHOLDER ALERT: Weiss Law Reminds BHVN, SWCH, ETTX, and TVTY Shareholders About Its Ongoing Investigations SHAREHOLDER ALERT: Weiss Law Reminds BHVN, SWCH, ETTX, and TVTY Shareholders About Its Ongoing Investigations PR Newswire NEW YORK, June 21, 2022 NEW YORK, June 21, 2022 /PRNewswire/ -- If...

SHAREHOLDER ALERT: Weiss Law Reminds BHVN, SWCH, ETTX, and TVTY Shareholders About Its Ongoing Investigations

INVESTIGATION ALERT: Halper Sadeh LLP Investigates FHLT, TVTY, MN, ETTX INVESTIGATION ALERT: Halper Sadeh LLP Investigates FHLT, TVTY, MN, ETTX PR Newswire NEW YORK, June 15, 2022 NEW YORK, June 15, 2022 /PRNewswire/ -- Halper Sadeh LLP, an investor rights law firm, is investigating the following...

INVESTIGATION ALERT: Halper Sadeh LLP Investigates FHLT, TVTY, MN, ETTX

SHAREHOLDER ALERT: Weiss Law Reminds ETTX, TVTY, MANT, and RTLR Shareholders About Its Ongoing Investigations SHAREHOLDER ALERT: Weiss Law Reminds ETTX, TVTY, MANT, and RTLR Shareholders About Its Ongoing Investigations PR Newswire NEW YORK, June 14, 2022 NEW YORK, June 14, 2022 /PRNewswire/ -- If...

SHAREHOLDER ALERT: Weiss Law Reminds ETTX, TVTY, MANT, and RTLR Shareholders About Its Ongoing Investigations

Entasis Therapeutics Holdings Inc. (NASDAQ:ETTX  Get Rating)  Cantor Fitzgerald issued their FY2023 EPS estimates for shares of Entasis Therapeutics in a research note issued to investors on Monday, June 6th. Cantor Fitzgerald analyst L. Chen forecasts that the company will earn ($1.06...

FY2023 Earnings Estimate for Entasis Therapeutics Holdings Inc. (NASDAQ:ETTX) Issued By Cantor Fitzgerald

WALTHAM, Mass., June 09, 2022 (GLOBE NEWSWIRE) -- EntasisTherapeutics Holdings Inc. (Nasdaq: ETTX), a late-stage clinical biopharmaceutical company focused on the discovery and development of novel antibacterial products, today announced multiple presentations at the American Society for ...

Entasis Therapeutics Presents Data on Sulbactam-Durlobactam and ETX0462 at 2022 ASM Microbe Annual Conference

Entasis Therapeutics Holdings, Inc. operates as a clinical stage biopharmaceutical company. It focuses on the discovery and development of novel antibacterial products for serious drug-resistant bacterial infections. Its anti-infective discovery platform has produced a pipeline of differentiated programs, which is bacterial infections, including ETX2514SUL (targeting Acinetobacter baumannii infections), ETX0282CPDP (targeting Enterobacteriaceae infections), Non-Beta-lactam PBP inhibitor, and Zoliflodacin. The company was founded in May 2015 and is headquartered in Waltham, MA.

Watchers	2,293
52-Wk Low	$1.40
52-Wk High	$3.88

Market Cap	$104.8M
Volume (M)	68,834.00
52-Wk High	$3.88
52-Wk Low	$1.40

Current Price	$2.19
Prev Close	$2.20
Open	$2.19
Dividend Yield	N/A
50-Day Moving Average	$2.07
Beta	0.49
Avg. Volume	152,600.19
PE Ratio	-1.95

52-Week High	$3.88
52-Week Low	$1.40
Market Capitalization	$104.8M
EPS	N/A
Price to Book	6.30
Revenue Per Employee	N/A
Enterprise Value/EBITDA	N/A

ETTX Entasis Therapeutics Holdings Inc

About

Feed

News

Fundamentals